Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants

Ying-Xin Fan1, Lily Wong1, Michael P Marino2

  • 1Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892.

Insights

Activating ERBB2 (Epidermal Growth Factor Receptor 2) mutations drive lung cancer by altering substrate preference. These ERBB2 mutants specifically phosphorylate GAB1, promoting tumor growth and signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Activating mutations in ERBB2 (Epidermal Growth Factor Receptor 2) kinase domain, like ERBB2(YVMA), are implicated in lung cancer development.
  • These mutations lead to uncontrolled cell signaling and tumor formation.

Purpose of the Study:

  • To investigate the role of GAB1 (Grb2-associated binder 1) in ERBB2 mutant-driven tumorigenesis.
  • To elucidate the mechanism by which ERBB2 mutants enhance GAB1 phosphorylation.

Main Methods:

  • Utilized dominant-negative GAB1 mutants and lentiviral shRNA to assess GAB1's requirement in ERBB2 mutant signaling.
  • Performed enzyme kinetic analysis to compare wild-type ERBB2 and ERBB2(YVMA) substrate specificity.
  • Measured in vitro phosphorylation rates of GAB1 protein by ERBB2 variants.

Main Results:

  • GAB1 hyper-phosphorylation is observed in ERBB2 mutant-expressing carcinomas and cell lines.
  • GAB1 phosphorylation is essential for ERBB2 mutant-induced cell signaling, transformation, and tumorigenesis.
  • ERBB2(YVMA) exhibits a significantly increased preference for GAB1 phosphorylation sites, with a ~150-fold higher specificity constant and ~70-fold faster in vitro phosphorylation rate compared to wild-type ERBB2.

Conclusions:

  • Acquired substrate preference for GAB1 is a critical mechanism in ERBB2 mutant-driven oncogenesis.
  • The ATP binding site and lapatinib sensitivity remain largely unchanged, distinguishing these mutants from EGFR lung cancer mutants.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...